מחקר זה יבדוק אם התרופה בטוחה, אם אנשים יכולים להתמודד עם השימוש בה, איך היא מתפשטת ומשתנה בגוף, ואיך היא פועלת במבוגרים בריאים. NBI-1065890 היא כדור שנחקר כדי לראות אם
מחקר זה יבדוק אם התרופה בטוחה, אם אנשים יכולים להתמודד עם השימוש בה, איך היא מתפשטת ומשתנה בגוף, ואיך היא פועלת במבוגרים בריאים. NBI-1065890 היא כדור שנחקר כדי לראות אם
Neurocrine Biosciences announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1065890 in healthy adult participants. NBI-1065890 is an
JPMorgan raised the firm’s price target on Neurocrine to $158 from $148 and keeps an Overweight rating on the shares. The analyst says the Phase 2 data for NBI-1117568 in
האנליסט חוזה כי תוצאות מניסוי שלב 2 של NBI-1117568 לטיפול בסכיזופרניה יהיו זמינות במחצית השנייה של 2024. החברה מגדירה הצלחה כשיפור של 10-13 נקודות לעומת פלצבו בסולם PANSS, המודד תסמיני
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neurocrine (NBIX – Research Report), Arcellx Inc (ACLX – Research Report) and Exact Sciences (EXAS – Research Report) with bullish sentiments.
Neurocrine (NBIX)
In a report issued on March 13, Brian Skorney from Robert W. Baird maintained a Buy rating on Neurocrine, with a price target of $157.00. The company’s shares closed last Thursday at $139.16, close to its 52-week high of $143.35.
According to TipRanks.com, Skorney is a 4-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Moderate Buy with an average price target of $150.33, representing a 6.0% upside. In a report issued on March 1, Jefferies also maintained a Buy rating on the stock with a $161.00 price target.
See the top stocks recommended by analysts >>
Arcellx Inc (ACLX)
In a report issued on March 13, Jack Allen from Robert W. Baird maintained a Buy rating on Arcellx Inc, with a price target of $77.00. The company’s shares closed last Thursday at $69.57, close to its 52-week high of $75.10.
According to TipRanks.com, Allen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcellx Inc with a $79.55 average price target, which is a 13.4% upside from current levels. In a report issued on March 7, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $81.00 price target.
Exact Sciences (EXAS)
In a report issued on March 13, Catherine Ramsey Schulte from Robert W. Baird assigned a Buy rating to Exact Sciences, with a price target of $82.00. The company’s shares closed last Thursday at $58.53, close to its 52-week low of $56.05.
According to TipRanks.com, Schulte is a 5-star analyst with an average return of
Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $91.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NBIX: